Business
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture ("JV") between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India.
About this update from Co-diagnostics, Inc.
[{"type":"text","content":"Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture ("JV") between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India.","length":561,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Co-Diagnostics)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Co-Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":184,"url":"https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_YQ2JYyHRV7RlBcYGBsF.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7a89e790bf1cbdd13a473c00e9766ccb","width":400,"height":184}},"href":"https://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"CoSara is currently supporting the second phase of the Company's preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the Co-Dx PCR point-of-care (PoC) platform*. Phase I of the MTB test studies included 354 clinical specimens from sputum and tongue swabs to provide early sensitivity and specificity assessments, while Phase II has evaluated 211 sputum specimens in a comparison evaluation against other tests to establish concordance for Mycobacterium tuberculosis detection. The studies are being conducted in preparation of advancement to clinical performance testing, required by Indian regulatory authorities prior to submission.","length":684,"tagName":"p"},{"type":"text","content":"Phase I of the preclinical studies for the 8-type HPV multiplex test, designed to identify the presence of eight different human papillomavirus genotypes, evaluated 286 clinic...